<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01968616</url>
  </required_header>
  <id_info>
    <org_study_id>KY-RV-R</org_study_id>
    <nct_id>NCT01968616</nct_id>
  </id_info>
  <brief_title>Ranibizumab Treatment for Retinal Vein Occlusion</brief_title>
  <official_title>Predictive Factors of 2-year Visual Outcome in Retinal Vein Occlusion Following Intravitreal Ranibizumab Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyoto University, Graduate School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyoto University, Graduate School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In retinal vein occlusion, predictive factors for visual outcome after ranibizumab treatment
      have not been evaluated comprehensively. Therefore, we have planned to analyze predictors for
      visual outcome from a viewpoint of electrophysiology and biomarkers besides morphological
      features by SD-OCT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean foveal thickness measured by SD-OCT</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Macular Edema Due to BRVO/CRVO</condition>
  <arm_group>
    <arm_group_label>Intravitreal Lucentis 0.5mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>One arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab, 0.5mg, Intravitreal</intervention_name>
    <arm_group_label>Intravitreal Lucentis 0.5mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form

          -  Male or female of aged 18 years or older

          -  Macula edema secondary to BRVO/CRVO

          -  Decrease of VA due to macular edema

        Exclusion Criteria:

          -  Prior episode of RVO

          -  Previous treatment with anti-VEGF drugs or corticosteroid or grid laser
             photocoagulation (study eye)

          -  Ocular disorders in the study eye that may confound interpretation of study results

          -  History of vitrectomy surgery, submacular surgery, or other surgical intervention for
             RVO

          -  The pregnant or lactating woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Ophthalmology, Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nagahisa Yoshimura, MD, PhD</last_name>
      <phone>+81-75-751-3248</phone>
      <email>nagaeye@kuhp.kyoto-u.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Akitaka Tsujikawa, MD. PhD</last_name>
      <phone>+81-75-751-3250</phone>
      <email>tujikawa@kuhp.kyoto-u.ac.jp</email>
    </contact_backup>
    <investigator>
      <last_name>Nagahisa Yoshimura, M.D, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2013</study_first_submitted>
  <study_first_submitted_qc>October 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2013</study_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyoto University, Graduate School of Medicine</investigator_affiliation>
    <investigator_full_name>Nagahisa Yoshimura</investigator_full_name>
    <investigator_title>Department of Ophthalmology &amp; Visual Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

